title: Clinically relevant suramin dosing regimen in mice with no effects against PC-3 prostate xenografts.
abstract: The goal of these studies was to develop a suramin dosing schedule that would maintain suramin plasma concentrations in mice in the 150-250 mu g/ml range. A high pressure liquid chromatography method was used to determine suramin plasma concentrations in mice. For pharmacokinetic studies CD2F(1) mice were treated intraperitoneally with 140 mg/kg of suramin. These pharmacokinetic data were used to develop a clinically relevant dosing regimen. To test the efficacy of this dosing regimen, athymic nude mice were implanted orthotopically with PC-3 prostate carcinoma cells, randomized, and treated intraperitoneally. The pharmacokinetically derived dosing regimen resulted in no antitumor effect against PC-3 prostate tumors. Suramin plasma concentrations ranged from 155 to 258 mu g/ml over the 14-day therapy period with tumor concentrations in the 53-241 mu g/g wet weight range.
authors: SO RES INST,BIRMINGHAM,AL 35255.
authors: B
authors: B
authors: Roberts
authors: K
authors: K
authors: Hook
authors: L
authors: L
authors: Whitfield
authors: C
authors: C
authors: Carter
authors: W
authors: W
authors: Elliott